New hope for Hard-to-Treat colorectal cancer: targeted drug enters human trials
NCT ID NCT07535112
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This early-stage trial tests a new drug, BAY 3771249, that targets a specific cancer-driving mutation called KRAS G12D. It is for people with advanced or metastatic colorectal cancer who have this mutation and have tried other treatments. The drug is given alone or with another cancer drug, cetuximab. The study aims to find a safe dose and see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BAY 3771249 (a drug that blocks the mutated KRAS G12D protein) and cetuximab (a cancer drug given by IV)
- What this could lead to
- If successful, this could lead to a new targeted treatment option for people with advanced colorectal cancer that has a specific KRAS G12D mutation, especially those who have run out of other options.
- What could go wrong
- This is an early Phase 1 trial, so the drug may not prove safe or effective. Side effects are unknown, and the mutation is rare, so results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Border Medical oncology - Albury Wodonga Regional Cancer Centre
NOT_YET_RECRUITINGAlbury, New South Wales, 2640, Australia
-
Cabrini Health Oncology Research
NOT_YET_RECRUITINGMalvern, Victoria, 3144, Australia
-
Calvary Mater Hospital Newcastle - Oncology
RECRUITINGWaratah, New South Wales, 2298, Australia
-
City of Hope - Duarte Cancer Center
NOT_YET_RECRUITINGDuarte, California, 91010, United States
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
NOT_YET_RECRUITINGRoma, 00128, Italy
-
Ghent University Hospital | Drug Research Unit Department
NOT_YET_RECRUITINGGhent, 9000, Belgium
-
HUS-Yhtymä, Helsingin yliopistollinen sairaala (HUS) - Syöpäkeskus
NOT_YET_RECRUITINGHelsinki, Uusimaa, 00029, Finland
-
Hospital Universitari Vall D Hebron | Oncologia
NOT_YET_RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario Hm Sanchinarro | Oncologia
NOT_YET_RECRUITINGMadrid, 28050, Spain
-
Icahn School of Medicine at Mount Sinai - Oncology
NOT_YET_RECRUITINGNew York, New York, 10029, United States
-
Karolinska Universitetssjukhuset - Fas I-enheten Solna CKC
NOT_YET_RECRUITINGStockholm, Stockholm County, 171 76, Sweden
-
Mayo Clinic - Cancer Center - Phoenix
NOT_YET_RECRUITINGPhoenix, Arizona, 85054, United States
-
NEXT Dallas - Oncology Department
RECRUITINGIrving, Texas, 75039, United States
-
National Cancer Center Singapore - Oncology Department
RECRUITINGSingapore, 168583, Singapore
-
National University Hospital Medical Centre
NOT_YET_RECRUITINGSingapore, 119074, Singapore
-
Nederlands Kanker Instituut
NOT_YET_RECRUITINGAmsterdam, North Holland, 1066 CX, Netherlands
-
Odense University Hospital - Oncology Department
NOT_YET_RECRUITINGOdense, Region Syddanmark, 5000, Denmark
-
Rigshospitalet - Kræftbehandling
NOT_YET_RECRUITINGCopenhagen, Capital Region, 2100, Denmark
-
START | San Antonio
NOT_YET_RECRUITINGSan Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
NOT_YET_RECRUITINGDenver, Colorado, 80218, United States
-
UC San Diego Health - Moores Cancer Center
NOT_YET_RECRUITINGSan Diego, California, 92037, United States